Company Directory

Global viral vector CDMO for cell and gene therapy

Oxford Biomedica (OXB) is a global contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy. The company provides lentiviral, adeno-associated virus (AAV), and adenoviral vector development and manufacturing services from early-stage process development through to commercial-scale GMP manufacture. OXB is headquartered in Oxford and operates manufacturing sites across Oxfordshire, France, and the United States.

Global biopharma with UK manufacturing, commercial and clinical operations

MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines into the Merck global network, alongside commercial and clinical development functions headquartered at Moorgate, London, and an Animal Health division based in Milton Keynes. MSD conducts approximately 150 clinical studies in the UK annually.

Global pharma company in immunology, vaccines, and oncology

GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines. The company operates major UK sites including its global R&D hub at Stevenage Bioscience Catalyst, manufacturing facilities at Barnard Castle, Ware, and Montrose, and its global headquarters in London's Knowledge Quarter.

Silica encapsulation platform eliminating cold chain for biologics

EnsiliTech is a biotechnology company developing ensilication, a patented platform technology that encases vaccines, antibodies, and other biologics within a silica matrix to render them thermally stable without refrigeration. The technology is applicable to existing and new biopharmaceutical formulations, enabling storage and transport at temperatures up to 50°C. EnsiliTech is developing applications across vaccines and monoclonal antibody therapeutics, with partners including the Centre for Process Innovation.

Infectious disease antigens and antibodies for diagnostics and research

The Native Antigen Company is a manufacturer of native and recombinant antigens, antibodies, and immunoassays for viral and bacterial infectious disease targets. Products are supplied to IVD manufacturers, pharmaceutical companies, and academic institutions for use in immunoassay development, serology, vaccine research, and quality control. Contract services include custom antigen manufacture, antibody generation, and assay development using a proprietary mammalian cell expression system for native-like protein production.

Lyophilisation equipment, CDMO services, and freeze-drying expertise

Biopharma Group is a contract development and manufacturing organisation and capital equipment supplier specialising in lyophilisation and liquid formulation technologies. The company serves pharmaceutical, biotechnology, and diagnostics clients across two divisions: an equipment sales and technical service division supplying freeze dryers, aseptic fill-finish lines, and cryogenic storage systems; and a CDMO division providing formulation development, cycle development, and GMP and non-GMP contract manufacturing.

Precision cancer vaccines to prevent metastatic recurrence

Infinitopes is a clinical-stage biotechnology company developing therapeutic cancer vaccines designed to prevent metastatic recurrence. Its lead candidate ITOP1 is a precision viral vector cancer vaccine targeting tumour antigens in patients with surgically resectable oesophageal adenocarcinoma, to be administered in the neoadjuvant setting while the primary tumour remains in situ. The VISTA Phase I/IIa trial received MHRA approval in April 2025 and is enrolling across UK specialist cancer centres.

Mammalian recombinant protein production and cell line development services

Daresbury Proteins is a contract research organisation specialising in mammalian recombinant protein production and cell line development. Using proprietary expression vectors optimised for CHO-K1 and HEK293 systems, the company produces difficult-to-express proteins as research reagents and candidate targets for pharmaceutical and biotechnology clients. Services include stable pool and clonal cell line generation, with cell lines transferable to third-party cGMP manufacturing settings. Background intellectual property has been licensed to Thermo Fisher Scientific.

Monoclonal antibodies for viral infectious disease

RQ Biotechnology is a passive immunisation company discovering and developing long-acting monoclonal antibodies to provide immediate protection against viral infections in immunocompromised and vulnerable populations. Founded by members of the UK COVID-19 Antibody Taskforce and co-founded with LifeArc, the company's pipeline spans influenza, RSV, and CMV. Its SARS-CoV-2 antibody programme was licensed to AstraZeneca and has progressed through Phase III trials.

Global biopharma with major UK R&D and regulatory operations

Pfizer Limited is the principal UK subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Its Sandwich, Kent site houses pharmaceutical sciences, global clinical supplies, quality assurance, and worldwide safety and regulatory operations serving over 175 markets. A Devices Centre of Excellence in Cambridge specialises in drug delivery device development. The UK operation supports clinical trials across dozens of UK sites and conducts R&D spanning small molecules, vaccines, oncology and inflammation.

Modular automated RNA manufacturing platform

Centillion is a UK biotech company whose platform integrates synthesis, purification, and formulation stages using continuous flow chemistry to produce mRNA and self-amplifying RNA at research and production scale. The platform supports process development through to regulatory-ready CMC packages and is available as a service, under licence, or through joint development programmes. First GMP installation was completed at Quotient Sciences in Alnwick in 2024.

Next-generation lipid nanoparticle platform for RNA vaccines and medicines

NeoVac is a biotechnology company developing a next-generation lipid nanoparticle platform to improve the delivery of RNA vaccines and therapeutics. Its library of fully biodegradable, tissue-targeted LNPs addresses limitations of first-generation formulations, offering enhanced thermostability, multiple routes of administration, and improved safety profiles. Applications span infectious disease vaccines, oncology, and broader RNA medicine programmes. NeoVac has advanced a Phase I mRNA vaccine candidate in UK volunteers.